December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
September 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
January 2023 in “Journal of The American Academy of Dermatology” Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
May 2021 in “Journal of the Endocrine Society” The case shows the importance of quick and thorough evaluation of adrenal tumors to prevent rapid disease progression and poor outcomes.
3 citations
,
September 2025 in “Frontiers in Immunology” JAK inhibitors are effective for treating moderate-to-severe alopecia areata.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking TYK2 might be a new way to treat hair loss from alopecia areata.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
July 2025 in “Journal of Investigative Dermatology” Upadacitinib effectively treats pyoderma gangrenosum.
55 citations
,
October 2015 in “Journal of Investigative Dermatology” Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.
1 citations
,
January 2022 in “Indian dermatology online journal” Fine needle aspiration with rapid on-site evaluation is useful for diagnosing pilomatrixoma.